| In-Vitro R&D |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
Cell De-Differentiation
Bioquark has tested BQ-A on several discrete cell types, in-vitro, to highlight the efficiency, speed
and versatility for general human tissue de-differentiation.
These cells, which in as rapidly as 24 hours, have all exhibited strong pluripotency morphology
and marker expression (including Oct ¾, Nanog, Sox-2, TRA-1-60, Rex-1, SSEA-1, SSEA-4, and
alkaline phosphatase), have included: BJ (Normal Foreskin Fibroblasts), HPA (Pre-Adipocytes),
Peripheral Blood CD4+Lymphocytes, MCBC (Mononuclear Cord blood Cells), Buccal Mucosa Cells
(Squamous Epithelial Cells), and BMSC (Bone Marrow Stromal Cells).
BJ (Foreskin Fibroblast) De-Differentiation
Bioquark has tested BQ-A on several discrete cell types, in-vitro, to highlight the efficiency, speed
and versatility for general human tissue de-differentiation.
These cells, which in as rapidly as 24 hours, have all exhibited strong pluripotency morphology
and marker expression (including Oct ¾, Nanog, Sox-2, TRA-1-60, Rex-1, SSEA-1, SSEA-4, and
alkaline phosphatase), have included: BJ (Normal Foreskin Fibroblasts), HPA (Pre-Adipocytes),
Peripheral Blood CD4+Lymphocytes, MCBC (Mononuclear Cord blood Cells), Buccal Mucosa Cells
(Squamous Epithelial Cells), and BMSC (Bone Marrow Stromal Cells).
BJ (Foreskin Fibroblast) De-Differentiation
Cell Re-Differentiation
Bioquark has also spent time demonstrating the plasticity of these BQ-A de-differentiated cells by
re-differentiating them via standard protocols, into tissue representing the CNS (neurons), with
heart (cardiomyocytes) and liver (hepatocytes) studies ongoing, highlighting control of fate in a
defined system.
MCBC (Mononuclear Cord blood Cells) Neural Re-Differentiation
Bioquark has also spent time demonstrating the plasticity of these BQ-A de-differentiated cells by
re-differentiating them via standard protocols, into tissue representing the CNS (neurons), with
heart (cardiomyocytes) and liver (hepatocytes) studies ongoing, highlighting control of fate in a
defined system.
MCBC (Mononuclear Cord blood Cells) Neural Re-Differentiation
Diseased Cell Re-Modeling
Bioquark has also studied the effect of BQ-A on diseased tissue types, HeLa (Cervical Carcinoma
Cells) and MCF-7 (Breast Adenocarcinoma Cells), with a third cell type, Glioma cells (Brain tumor)
ongoing, to investigate effects in genetically damaged cells, and encountered results of
substantial interest: both cell types de-differentiated, but did not return to their cancerous,
uncontrolled growth patterns.
De-differentiation of human cervical carcinoma (HeLa) cells
Bioquark has also studied the effect of BQ-A on diseased tissue types, HeLa (Cervical Carcinoma
Cells) and MCF-7 (Breast Adenocarcinoma Cells), with a third cell type, Glioma cells (Brain tumor)
ongoing, to investigate effects in genetically damaged cells, and encountered results of
substantial interest: both cell types de-differentiated, but did not return to their cancerous,
uncontrolled growth patterns.
De-differentiation of human cervical carcinoma (HeLa) cells
As a result, Bioquark Inc. was encouraged not only in the potential of direct pharmaceutical
application of BQ-A in regeneration, but also for an unparalleled approach to natural
reprogramming and repair.
BQ-A Direct Therapeutic Reprogramming Premise
Based on the facts that:
1) an oocyte directed, genome-wide rewinding naturally occurs post-conception, whereby
epigenetic alterations and DNA damage are erased in the embryo, by intrinsic reprogramming and
repair processes,
and
2) most chronic diseases, including cancer, are associated with the effects of various lifestyle,
environmental, and age-related genetic damage,
then Bioquark's unique approach to mimicing the biochemical potential of the living oocyte via
BQ-A, and targeting, in-vivo, de-differentiation and re-differentiation, has the potential to lead to
cellular rejuvenation, stability, and repair in most human tissues.
application of BQ-A in regeneration, but also for an unparalleled approach to natural
reprogramming and repair.
BQ-A Direct Therapeutic Reprogramming Premise
Based on the facts that:
1) an oocyte directed, genome-wide rewinding naturally occurs post-conception, whereby
epigenetic alterations and DNA damage are erased in the embryo, by intrinsic reprogramming and
repair processes,
and
2) most chronic diseases, including cancer, are associated with the effects of various lifestyle,
environmental, and age-related genetic damage,
then Bioquark's unique approach to mimicing the biochemical potential of the living oocyte via
BQ-A, and targeting, in-vivo, de-differentiation and re-differentiation, has the potential to lead to
cellular rejuvenation, stability, and repair in most human tissues.
